All In Biotech

Drug Trial Radar · NCT05054387

China Post-marketing Surveillance (PMS) Study of Fabrazyme®

A Phase 4, Open Label, Safety and Efficacy Study of Fabrazyme® (Agalsidase Beta) as Enzyme Replacement Therapy in Chinese Participants With Fabry Disease

Last checked: Nov 20, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Oct 13, 2021

Primary completion

Mar 9, 2023

Study completion Mar 9, 2023

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Sep 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with Fabry Disease.

Conditions

  • Fabry Disease

Interventions

  • Agalsidase betaDrug

    Powder for concentration into a solution Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (AEs)Time frame: Baseline to week 50

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number :1560003

    Beijing, China

  • Investigational Site Number :1560002

    Beijing, China

  • Investigational Site Number :1560001

    Shanghai, China

  • Investigational Site Number :1560004

    Shanghai, China

  • Investigational Site Number :1560006

    Taiyuan, China

  • Investigational Site Number :1560005

    Wuhan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.